We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

193 hedge funds and large institutions have $1.48B invested in Heron Therapeutics in 2021 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 67 increasing their positions, 63 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

397% more call options, than puts

Call options by funds: $19.8M | Put options by funds: $3.99M

25% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 24

2% more funds holding

Funds holding: 189 → 193 (+4)

6% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 63

0.36% more ownership

Funds ownership: 99.36% → 99.71% (+0.36%)

22% less capital invested

Capital invested by funds: $1.91B → $1.48B (-$428M)

75% less funds holding in top 10

Funds holding in top 10: 4 → 1 (-3)

Holders
193
Holders Change
+4
Holders Change %
+2.12%
% of All Funds
3.39%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
30
Increased
67
Reduced
63
Closed
24
Calls
$19.8M
Puts
$3.99M
Net Calls
+$15.9M
Net Calls Change
+$14.1M

Top Buyers

1
UOC
UBS O'Connor
Illinois
+$30.8M
2
Millennium Management
Millennium Management
New York
+$15M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$11M
4
State Street
State Street
Massachusetts
+$10.7M
5
SCM
Suvretta Capital Management
New York
+$9.02M

Top Sellers

1
Artisan Partners
Artisan Partners
Wisconsin
-$28.4M
2
O
OrbiMed
New York
-$25.2M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$19.4M
4
ITP
Iron Triangle Partners
Connecticut
-$18.3M
5
Norges Bank
Norges Bank
Norway
-$10.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
201
Athanor Capital
New York
– -$400K -18,885 Closed
APP
202
Alpha Paradigm Partners
Illinois
– -$395K -18,645 Closed
WG
203
Winton Group
United Kingdom
– -$288K -13,621 Closed
OC
204
Oppenheimer & Co
New York
– -$231K -10,900 Closed
HIIFS
205
Harel Insurance Investments & Financial Services
Israel
– -$681K -10,000 Closed
SAM
206
Shell Asset Management
Netherlands
– -$180K -8,523 Closed
BAM
207
Belpointe Asset Management
Nevada
– -$166K -7,871 Closed
CTFG
208
Capstone Triton Financial Group
Oklahoma
– -$21K -1,000 Closed
SFS
209
Sowell Financial Services
Arkansas
– -$14K -676 Closed
BSSFA
210
Baron Silver Stevens Financial Advisors
Florida
– -$2K -125 Closed
GEA
211
Glen Eagle Advisors
New Jersey
– -$2.12K -100 Closed
ABC
212
Associated Banc-Corp
Wisconsin
– -$1K -69 Closed
JCM
213
Jacobi Capital Management
Pennsylvania
– -$1K -41 Closed
FWM
214
Filbrandt Wealth Management
Wisconsin
– +$267 +15 New
5 6 7 8
9

HRTX Hedge Fund Activity: Q1 2021 in Review

193 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2021, worth a combined $1.48B — down 22% from $1.91B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new HRTX positions and 24 closed out — a net gain of 6 holders — while 67 added to existing stakes and 63 trimmed.

The largest buyer was UBS O'Connor, adding an estimated $30.8M. The largest seller was Artisan Partners, exiting entirely with an estimated $28.4M sold.

  • 193 institutional investors held Heron Therapeutics (HRTX) as of Q1 2021, up from 189 in Q4 2020.
  • Funds reported $1.48B of Heron Therapeutics stock for Q1 2021, down 22% quarter-over-quarter.
  • 30 funds opened new Heron Therapeutics positions in Q1 2021 and 24 closed out, a net change of +6 holders.
  • The largest Heron Therapeutics buyer in Q1 2021 was UBS O'Connor, an estimated $30.8M added.
  • The largest Heron Therapeutics seller in Q1 2021 was Artisan Partners, an estimated $28.4M sold.

Based on aggregated 13F filings for Q1 2021.